Clinical scientist

Jasper Therapeutics Announces Appointment of Edwin J. Tucker, M.D., as Chief Medical Officer

Retrieved on: 
Tuesday, June 13, 2023

REDWOOD CITY, Calif., June 13, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Dr. Edwin J. Tucker as Jasper’s Chief Medical Officer. Concurrently, Jasper also announced the appointment of Dr. Daniel Adelman, who had been serving as Jasper’s Acting Chief Medical Officer, to its Scientific Advisory Board and to the position of Senior Clinical Advisor.

Key Points: 
  • Concurrently, Jasper also announced the appointment of Dr. Daniel Adelman, who had been serving as Jasper’s Acting Chief Medical Officer, to its Scientific Advisory Board and to the position of Senior Clinical Advisor.
  • He was most recently Chief Medical Officer at Goldfinch Bio, where he led clinical development and helped build the regulatory, medical affairs and clinical operations functions.
  • Dr. Adelman has held several leadership roles within the biopharma industry throughout his career, including Chief Medical Officer at Aimmune Therapeutics, Alvine Pharmaceuticals and Sunesis Pharmaceuticals.
  • In connection with the appointment of Dr. Tucker as its Chief Medical Officer, on June 12, 2023, Jasper granted Dr. Tucker an option to purchase 400,000 shares of voting common stock (the “Option”).

Jasper Therapeutics Appoints Daniel Adelman, M.D., as Acting Chief Medical Officer

Retrieved on: 
Thursday, March 23, 2023

“We are delighted to welcome Dan to the Jasper team as Acting Chief Medical Officer,” said Ron Martell, CEO of Jasper Therapeutics.

Key Points: 
  • “We are delighted to welcome Dan to the Jasper team as Acting Chief Medical Officer,” said Ron Martell, CEO of Jasper Therapeutics.
  • “Dr.
  • Adelman is an extremely experienced drug developer and leader in the field of immune-based therapeutics and has an impressive track record of success in bringing new drugs to market.
  • Dr. Adelman has held several leadership roles within the biopharma industry throughout his career, including Chief Medical Officer at Aimmune Therapeutics, Alvine Pharmaceuticals and Sunesis Pharmaceuticals.

Girls Inc. of San Diego County Welcomes Cinnamon Clark, Melissa Marin, Manaleage Tedemet and Lina Yisehak to its Board of Directors

Retrieved on: 
Friday, April 15, 2022

SAN DIEGO, April 15, 2022 /PRNewswire/ -- Girls Inc. of San Diego County welcomes four new members to its board of directors.

Key Points: 
  • SAN DIEGO, April 15, 2022 /PRNewswire/ -- Girls Inc. of San Diego County welcomes four new members to its board of directors.
  • "Along with the rest of our board, our new members will have a pivotal role, bringing valuable insights to impact the lives of underserved girls throughout San Diego."
  • Cinnamon Clark is the Practice Lead for Diversity, Equity and Inclusion Services at McLean & Company, where she leads the development of DEI strategy.
  • She has a history of volunteerism within the San Diego community for non-profits such as Girl's Think Tank and Junior Achievement of San Diego.

CHAIR Renewal and Enhanced Strategic Direction

Retrieved on: 
Tuesday, March 29, 2022

Over the past 8 years, with the help of its leadership and members, CHAIR has completed many milestones with successful accomplishments.

Key Points: 
  • Over the past 8 years, with the help of its leadership and members, CHAIR has completed many milestones with successful accomplishments.
  • Over the past sixmonths, CHAIR (Coalition for Healthcare Acquired Infection Reduction) has been going through a thoughtful and comprehensive renewal with the assistance of LIFT Impact Partners and several stakeholderworkshop meetings.
  • CHAIRs new Strategic Roadmap for 2022 - 2026 will be led by Steve Reinecke, selected as the new Interim Executive Director.
  • We are excited about the new mission and focus for CHAIR, and the leadership Steve Reinecke brings to this organization, said Richard Dixon, cofounder of CHAIR.

NAMSA Announces Intent to Acquire Contract Research Organization, ÅKRN

Retrieved on: 
Monday, March 21, 2022

NAMSA , a world leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, announced today its intent to acquire KRN Scientific Consulting , a prominent European Medical Device CRO based in Madrid, Spain.

Key Points: 
  • NAMSA , a world leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, announced today its intent to acquire KRN Scientific Consulting , a prominent European Medical Device CRO based in Madrid, Spain.
  • We are thrilled to welcome KRN to NAMSA, said Dr. Christophe Berthoux , CEO of NAMSA.
  • Helping medical device Sponsors improve healthcare since 1967, NAMSA is the worlds leading MedTech Contract Research Organization (CRO) offering global end-to-end development services.
  • KRN offers optimized regulatory and clinical services tailored to MedTech Clients and Partners in a cost-conscious and diligent manner.

Congenica Expands its Clinical Consulting Services

Retrieved on: 
Thursday, January 13, 2022

Cambridge, United Kingdom 13 January 2022 - Congenica , the digital health company enabling rapid and accurate analysis of complex genomic data to transform peoples lives, today announces the expansion of its range of clinical consulting services.

Key Points: 
  • Cambridge, United Kingdom 13 January 2022 - Congenica , the digital health company enabling rapid and accurate analysis of complex genomic data to transform peoples lives, today announces the expansion of its range of clinical consulting services.
  • In addition to the services already offered by Congenica, the Company has launched a new sample to report service, providing additional access to sequence providers when the clients laboratory has limited sequencing capacity.
  • Congenicas in-house team of Clinical Scientists already offer bespoke services for a global customer base, providing as much or as little support as needed to help laboratories meet demand, scale operations and deliver gold standard service for their customers.
  • Victoria Hewitt, Lead, Clinical Interpretation Services at Congenica, said: By broadening the range of our clinical consulting services we can meet the varying demands of our customers, providing full support from sample to report, whilst working with them to develop flexible solutions.

Congenica Expands its Clinical Consulting Services

Retrieved on: 
Thursday, January 13, 2022

Cambridge, United Kingdom 13 January 2022 - Congenica , the digital health company enabling rapid and accurate analysis of complex genomic data to transform peoples lives, today announces the expansion of its range of clinical consulting services.

Key Points: 
  • Cambridge, United Kingdom 13 January 2022 - Congenica , the digital health company enabling rapid and accurate analysis of complex genomic data to transform peoples lives, today announces the expansion of its range of clinical consulting services.
  • In addition to the services already offered by Congenica, the Company has launched a new sample to report service, providing additional access to sequence providers when the clients laboratory has limited sequencing capacity.
  • Congenicas in-house team of Clinical Scientists already offer bespoke services for a global customer base, providing as much or as little support as needed to help laboratories meet demand, scale operations and deliver gold standard service for their customers.
  • Victoria Hewitt, Lead, Clinical Interpretation Services at Congenica, said: By broadening the range of our clinical consulting services we can meet the varying demands of our customers, providing full support from sample to report, whilst working with them to develop flexible solutions.

ArborMetrix Announces Maria Siambekos as New CEO

Retrieved on: 
Wednesday, May 19, 2021

"Sheis a proven leaderwith decades of healthcare technology, experience, unmatchedexpertise, and the ability toachieve operational excellence.Maria\'svision for howhealthcaretechnologies can make an immediate andmeasurableimpactis what ArborMetrix needs as the companysteps intoits nextstage ofexpanded product innovation and growth.

Key Points: 
  • "Sheis a proven leaderwith decades of healthcare technology, experience, unmatchedexpertise, and the ability toachieve operational excellence.Maria\'svision for howhealthcaretechnologies can make an immediate andmeasurableimpactis what ArborMetrix needs as the companysteps intoits nextstage ofexpanded product innovation and growth.
  • "To achieve improved outcomes and higher quality care, we need toleverage data and insights tobetter understandwhy it happens, and how to improve.ArborMetrixdelivers this clarity today, and I\'m excitedabout its future and potential impact on the healthcare industry.
  • "\nPrior to joiningArborMetrix, Mariaserved ina multitude ofexecutive leadership roles at such companies asVynca,Healthbox,GE Healthcare,andTheraDoc.Shebegan her career as clinical scientist at The University of Chicago.
  • Learn more at ArborMetrix.com .\nView original content to download multimedia: http://www.prnewswire.com/news-releases/arbormetrix-announces-maria-siam...\n'